Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2023 Net Income-$19.39M-$19.39MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$20,261,000N/M Operating Cash Flowderived-$9,144,000N/M Free Cash Flowderived-$9,197,000N/M ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end